Cerebrolysin is best understood as a named biological preparation, not as one peptide with a single amino-acid sequence. That distinction matters whenever a study is used to support a differently labeled product. Matching a broad ingredient description is not the same as matching the material actually investigated.
The Hong Kong product registry identifies a specific Cerebrolysin injection as a porcine-brain-derived peptide preparation and classifies that registered product as prescription-only. This is a jurisdiction-specific record. It does not establish that another product sold online has the same composition, regulatory status or manufacturing controls.
Why the manufacturing process matters
For a mixture, identity includes more than total peptide content. Two preparations can share an animal-tissue origin yet differ in the distribution of components, processing and measured activity. A percentage-purity statement does not necessarily describe all of those properties.
A 2024 laboratory comparison found different peptide profiles and bioassay results among the tested preparations. That observation supports caution about interchangeability. It is not a clinical trial proving that one product improves patients' outcomes more than every alternative.
The useful question is therefore not simply whether a vial contains peptides. It is whether its composition, quality specifications and clinical evidence match the particular claim being made. A shared generic-sounding description cannot answer that question by itself.
What a reader can and cannot infer
A paper about the named clinical preparation cannot authenticate an unrelated research-catalog vial. Nor does a chemical fingerprint establish that a preparation is appropriate for a particular neurological symptom. Product identity and treatment effectiveness are separate evidence requirements.
This also changes how comparisons should be read. An experiment comparing a handful of samples is not a worldwide survey of all manufacturers or batches. A cell assay is not a substitute for patient-centered outcomes, and regulatory recognition in one country is not universal authorization.
For a clinical discussion, the exact preparation, local prescribing status and proposed indication should be identified before applying any study. Until those pieces align, substituting “cerebroprotein,” “brain peptides” and “Cerebrolysin” in an evidence summary risks claiming a level of equivalence that has not been demonstrated.